Keith R Stayrook
Overview
Explore the profile of Keith R Stayrook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou J, Gemperline D, Turner M, Oldach J, Molignano J, Sims J, et al.
Immunohorizons
. 2021 Oct;
5(10):830-843.
PMID: 34702760
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects up to one in five children and millions of adults in developed countries. Clinically, AD skin lesions manifest as...
2.
Lugar C, Clarke C, Morphy R, Rudyk H, Sapmaz S, Stites R, et al.
J Med Chem
. 2021 Apr;
64(9):5470-5484.
PMID: 33852312
The Th17 pathway has been implicated in autoimmune diseases. The retinoic acid receptor-related orphan receptor C2 (RORγt) is a master regulator of Th17 cells and controls the expression of IL-17A....
3.
Shao Y, Wichern E, Childress P, Adaway M, Misra J, Klunk A, et al.
Am J Physiol Endocrinol Metab
. 2019 Jan;
316(5):E749-E772.
PMID: 30645175
A goal of osteoporosis therapy is to restore lost bone with structurally sound tissue. Mice lacking the transcription factor nuclear matrix protein 4 (, , , ) respond to several...
4.
Zheng J, Chang M, Stites R, Wang Y, Bruning J, Pascal B, et al.
Nat Commun
. 2017 Oct;
8(1):923.
PMID: 29030554
The vitamin D receptor/retinoid X receptor-α heterodimer (VDRRXRα) regulates bone mineralization via transcriptional control of osteocalcin (BGLAP) gene and is the receptor for 1α,25-dihydroxyvitamin D (1,25D3). However, supra-physiological levels of...
5.
Clinkenbeard E, Hanudel M, Stayrook K, Appaiah H, Farrow E, Cass T, et al.
Haematologica
. 2017 Aug;
102(11):e427-e430.
PMID: 28818868
No abstract available.
6.
Shao Y, Hernandez-Buquer S, Childress P, Stayrook K, Alvarez M, Davis H, et al.
Endocrinology
. 2017 Jun;
158(9):2722-2740.
PMID: 28637206
Combining anticatabolic agents with parathyroid hormone (PTH) to enhance bone mass has yielded mixed results in osteoporosis patients. Toward the goal of enhancing the efficacy of these regimens, we tested...
7.
Childress P, Stayrook K, Alvarez M, Wang Z, Shao Y, Hernandez-Buquer S, et al.
Mol Endocrinol
. 2015 Aug;
29(9):1269-85.
PMID: 26244796
PTH is an osteoanabolic for treating osteoporosis but its potency wanes. Disabling the transcription factor nuclear matrix protein 4 (Nmp4) in healthy, ovary-intact mice enhances bone response to PTH and...
8.
Stayrook K, Mack J, Cerabona D, Edwards D, Bui H, Niewolna M, et al.
Bonekey Rep
. 2015 Jul;
4:719.
PMID: 26157579
Mechanistic understanding of the preferential homing of circulating tumor cells to bone and their perturbation on bone metabolism within the tumor-bone microenvironment remains poorly understood. Alteration in both transforming growth...
9.
Carson M, Zhang J, Chalmers M, Bocchinfuso W, Holifield K, Masquelin T, et al.
Bioorg Med Chem Lett
. 2014 Jun;
24(15):3459-63.
PMID: 24974344
Modulation of the vitamin D receptor (VDR) with a ligand has the potential to be useful for the oral treatment of osteoporosis. One component of our lead generation strategy to...
10.
Chiechi A, Waning D, Stayrook K, Buijs J, Guise T, Mohammad K
Adv Biosci Biotechnol
. 2014 Feb;
4(10C):15-30.
PMID: 24558636
Breast cancer is the most prevalent cancer among females worldwide leading to approximately 350,000 deaths each year. It has long been known that cancers preferentially metastasize to particular organs, and...